BIO-key Intl Q2 EPS $(0.16) Beats $(0.23) Estimate, Sales $1.93M Miss $2.30M Estimate
Portfolio Pulse from Benzinga Newsdesk
BIO-key Intl reported Q2 losses of $(0.16) per share, beating the analyst consensus estimate of $(0.23) by 30.43%. However, the company's quarterly sales of $1.93 million missed the analyst consensus estimate of $2.30 million by 16.13%. This represents a 0.93% decrease over sales of $1.95 million the same period last year.
August 14, 2023 | 9:44 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BIO-key Intl's Q2 earnings beat estimates but sales missed, indicating mixed performance.
BIO-key Intl's earnings beat estimates, which is positive for the stock. However, the company's sales missed estimates, which is negative. These two factors could offset each other, leading to a neutral short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100